Yazar "Bakirtas, Mehmet" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin's Lymphoma: A Multi-Center Retrospective Study on Survival and Safety
    (Springer India, 2025) Bakirtas, Mehmet; Hindilerden, Ipek Yonal; Ulu, Bahar Uncu; Ekinci, Omer; Dogu, Mehmet Hilmi; Aydogdu, Ismet; Berber, Ilhami
    Background Refractory/relapsed classical Hodgkin's lymphoma (R/RcHL) poses significant treatment challenges, with limited success rates in achieving long-term remission. Brentuximab Vedotin (BV), an anti-CD30 monoclonal antibody-drug conjugate, has emerged as a promising therapeutic option. This study aims to evaluate the efficacy and safety of BV monotherapy in R/RcHL patients, particularly regarding survival outcomes and adverse events. Methods This multi-center retrospective study included 82 R/RcHL patients aged 18 and over, treated with BV monotherapy across 14 institutions in Turkey from June 2012 to June 2020. Data on demographics, clinical characteristics, treatment response, adverse events, and overall survival (OS) rates were collected and analyzed. Primary outcomes were overall treatment response rate and OS, while the secondary outcome focused on the adverse event profile of BV treatment. Results Among the patients (56.1% female, median age 33.5 years), the overall treatment response rate was 76.8%. The median OS was 13.6 months, with patients undergoing hematopoietic stem cell transplantation (HSCT) post-BV treatment exhibiting significantly longer survival (19.6 months) compared to those who did not receive HSCT (7.8 months, p < 0.001). Grade 3 to 5 adverse events were observed in 32.9% of patients, with neutropenia being the most common. Conclusion BV monotherapy demonstrates substantial efficacy in treating R/RcHL, offering a favorable balance between treatment response and manageable adverse events. Particularly effective as a bridging therapy to HSCT, BV significantly extends survival in R/RcHL patients. These findings underscore the need for prospective studies to further delineate patient subsets most likely to benefit from BV monotherapy.
  • Küçük Resim Yok
    Öğe
    Real-World Efficacy and Safety of Ruxolitinib in Steroid-Refractory Graft-Versus-Host Disease: A Multicenter Retrospective Study From Turkey
    (Cig Media Group, Lp, 2025) Bakirtas, Mehmet; Berber, Lhami; Hindilerden, Ipek Yonal; Dal, Mehmet Sinan; Guner, Sebnem Izmir; Uysal, Ayse; Ekinci, Omer
    [No abstract available]
  • Küçük Resim Yok
    Öğe
    Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from Turkey
    (Mdpi, 2026) Bakirtas, Mehmet; Berber, Ilhami; Hindilerden, Ipek Yonal; Dal, Mehmet Sinan; Izmir Guner, Sebnem; Uysal, Ayse; Ekinci, Omer
    Introduction & Objective: Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), with limited treatment options for steroid-resistant cases. Ruxolitinib, a JAK1/2 inhibitor, has shown promise in treating steroid-resistant acute (aGVHD), chronic (cGVHD), and overlap GVHD (oGVHD), but real-world data remain limited. This study evaluated the real-world efficacy and safety of ruxolitinib in allo-HSCT patients with steroid-resistant GVHD. Materials & Methods: This retrospective, multicenter study included adult patients treated with ruxolitinib for Grade II or higher aGVHD or moderate-to-severe cGVHD at nine centers in Turkey (2017-2024). Clinical characteristics, treatment responses, and adverse events were recorded. Primary outcomes were overall response rate (ORR) and overall survival (OS). Results: Among 80 patients (mean age: 39.3 +/- 13.3 years; 60 males), 39 had aGVHD, 68 cGVHD, and 15 oGVHD. The ORR was 72 of 80 patients (90.0%) (complete response: 37 of 80 [46.3%], partial response: 35 of 80 [43.8%]). The 1-year and 2-year OS rates were 91.3% and 82.5%. Severe cGVHD (p < 0.001) and lack of response to ruxolitinib (p = 0.018) were associated with reduced OS. Adverse events included infections in 40 of 80 patients (50.0%), cytopenias in 23 of 80 (28.7%), and cytomegalovirus reactivation in 20 of 80 (25.0%). Conclusion: In this retrospective multicenter cohort, ruxolitinib was associated with high response rates in steroid-refractory GVHD, while disease severity remained a key determinant of survival, and findings should be interpreted as exploratory.